Impaired glucose tolerance and neuropathy

Neurologist

Volumn 14, Issue 1, 2008, Pages 23-29

  Smith, A Gordon ^a   Singleton, J Robinson ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Impaired glucose tolerance; Metabolic syndrome; Peripheral neuropathy

Indexed keywords

METFORMIN;

CLINICAL FEATURE; DIABETIC NEPHROPATHY; DIET THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; GLYCEMIC CONTROL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; KINESIOTHERAPY; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

DIABETIC NEUROPATHIES; DISEASE PROGRESSION; GLUCOSE; HUMANS; METABOLIC SYNDROME X; MICROCIRCULATION; NERVE FIBERS, UNMYELINATED; PERIPHERAL NERVES; PERIPHERAL NERVOUS SYSTEM DISEASES; RISK REDUCTION BEHAVIOR;

EID: 38349063153     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/NRL.0b013e31815a3956     Document Type: Review

References (49)

1. Gregg EW, Sorlie P, Paulose-Ram R, et al. Prevalence of lowerextremity disease in the US adult population ≥40 years of age with and without diabetes: 1999-2000 national health and nutrition examination survey. Diabetes Care. 2004;27:1591-1597.
2. Stovner L, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27:193-210.
3. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26(Suppl 1):S5-S20.
4. Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care. 2006;29:1263-1268.
5. Harris MI, Hadden WC, Knowler WC, et al. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in the US population age 20-74 years. Diabetes. 1987;36:523-534.
6. Hiltunen L, Laara E, Keinanen-Kiukaanniemi S. Changes in glucose tolerance during three year's follow-up in an elderly population. Public Health. 1999;113:181-184.
7. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
8. Tominga M, Eguchi H, Igarashi K, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999;22:920-924.
9. Kuller LH, Velentgas P, Barzilay J, et al. Diabetes mellitus: subclinical cardiovascular disease and risk of incident cardiovascular disease and all-cause mortality. Arterioscler Thromb Vasc Biol. 2000;20:823-829.
10. the European Diabetes Epidemiology Group. DECODE Study Group, Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161:397-405.
11. Metcalf PA, Baker JR, Scragg RK, et al. Microalbuminuria in a middle-aged workforce. Effect of hyperglycemia and ethnicity. Diabetes Care. 1993;16:1485-1493.
12. Pan XR, Hu YH, Li GW, et al. Impaired glucose tolerance and its relationship to ECG-indicated coronary heart disease and risk factors among Chinese. Da Qing IGT and diabetes study. Diabetes Care. 1993;16:150-156.
13. Klein R, Barrett-Conner E, Blunt B, et al. Visual impairment and retinopathy in people with normal glucose tolerance, impaired glucose toelrance, and newly diagnosed NIDDM. Diabetes Care. 1991;14:914-918.
14. Smith AG, Singleton JR. The diagnostic yield of a standardized approach to idiopathic sensory-predominant neuropathy. Arch Intern Med. 2004;164:1021-1025.
15. Sumner C, Seth S, Griffin J, et al. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology. 2003;60:108-111.
16. Novella SP, Inzucchi SE, Goldstein JM. The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy. Muscle Nerve. 2001;24:1229-1231.
17. Thomas PK. Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. Diabetes. 1997;Suppl 2:S54-S57.
18. Russell J, Karnes J, Dyck P. Sural nerve myelinated fiber density differences assoicated with meaningful changes in clinical and electrophysiologic measurements. J Neurol Sci. 1996;135:114-117.
19. Singleton JR, Smith AG, Bromberg MB. Painful sensory neuropathy associated with impaired glucose tolerance. Muscle Nerve. 2001;24:1225-1228.
20. Smith AG, Tripp C, Singleton JR. Skin biopsy findings in patients with neuropathy associated with diabetes and impaired glucose tolerance. Neurology. 2001;57:1701.
21. McDaid EA, Monaghan B, Parker AI, et al. Peripheral autonomic impairment in patients newly diagnosed with type II Diabetes. Diabetes Care. 1994;17:1422-1427.
22. Smith AG, Russell J, Feldman EL, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. 2006;29:1294-1299.
23. Burchiel KJ, Russell LC, Lee RP, et al. Spontaneous activity of primary afferent neurons in diabetic BB/wistar rats: a possible mechanism of chronic diabetic neuropathic pain. Diabetes. 1985;36:1210-1213.
24. Boulton A. What causes neuropathic pain? J Diab Comp. 1992;6:58-63.
25. Singleton JR, Smith AG, Russell JW, et al. Microvascular complications of impaired glucose tolerance. Diabetes. 2003;52:2867-2873.
26. Russell J, Sullivan K, Windebank A, et al. Neurons undergo apoptosis in animal and cell culture models of diabetes. Neurobiol Dis. 1999;6:347-363.
27. Veves A, Akbari CM, Primavera J, et al. Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes. 1998;47:457-463.
28. Smith AG, Robinson Singleton J. Idiopathic neuropathy, prediabetes and the metabolic syndrome. J Neurol Sci. 2006;242:9-14.
29. Martin CL, Albers J, Herman WH, et al. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care. 2006;29:340-344.
30. Diabetes Control and Complications Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med. 1993;329:977-986.
31. Navaro X, Sutherland DE, Kennedy WR. Long-term effects of pancreatic transplantation on diabetic neuropathy. Ann Neurol. 1997;42:727-736.
32. Tuomilehto J, Lindstrom J, Eriksson J, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.
33. Singleton JR, Bixby B, Feldman EL, et al. Diet and exercise counseling alone does not prevent long-term neuropathy progression in IGTN. Neurology. 2007;68:A410.
34. The Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults. The Third Report of the ATP III. National Institutes of Health National Heart Lung and Blood Institute, Bethesda Maryland 2001; NIH publication 01-3670. Available at http://www.nhlbi.nih.gov/guidelines/cholesterol/index. htm.
35. Yudkin JS. Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent? Diabetes Care. 1999;22(Suppl 3):C25-C30.
36. Reaven GM, Chen YD, Jeppesen J, et al. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest. 1993;92:141-146.
37. Isomaa B, Henricsson M, Almgren P, et al. The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia. 2001;44:1148-1154.
38. Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome. Lancet. 2005;366:1921-1922; author reply 1923-1924.
39. Costa LA, Canani LH, Lisboa HR, et al. Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic complications in Type 2 diabetes. Diabet Med. 2004;21:252-255.
40. Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352:341-350.
41. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393.
42. Hughes RA, Umapathi T, Gray IA, et al. A controlled investigation of the cause of chronic idiopathic axonal polyneuropathy. Brain. 2004;127:1723-1730.
43. Periquet MI, Novak V, Collins MP, et al. Painful sensory neuropathy prospective evaluation using skin biopsy. Neurology. 1999;53:1641-1647.
44. Rose K, Singleton JR, Smith AG. Increased prevalence of metabolic syndrome in peripheral neuropathy. Neurology. 2006;65:103.
45. Lewis GF, Carpentier A, Adeli K, et al. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev. 2002;23:201-229.
46. Esenabhalu VE, Schaeffer G, Graier WF. Free fatty acid overload attenuates Ca2+ signaling and NO production in endothelial cells. Antioxid Redox Signal. 2003;5:147-153.
47. Pleiner J, Schaller G, Mittermayer F, et al. FFA-induced endothelial dysfunction can be corrected by vitamin C. J Clin Endocrinol Metab 2002;87:2913-2917.
48. Boyanovsky B, Karakashian A, King K, et al. Uptake and metabolism of low density lipoproteins with elevated ceramide content by human microvascular endothelial cells: implications for the regulation of apoptosis. J Biol Chem. 2003;278:26992-26999.
49. Ukkola O, Santaniemi M. Adiponectin: a link between excess adiposity and associated comorbidities? J Mol Med. 2002;80:696-702.